Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

被引:269
作者
Berger, C
Flowers, ME
Warren, EH
Riddell, SR
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1182/blood-2005-08-3503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft versus host disease. However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination. We show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CID8(+) and CD4(+) T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells. Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and cluantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes. Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells. These studies demonstrate the need for nonimmunogenic suicide genes and identify a strategy for detection of CD4(+) and CD8(+) T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials. The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.
引用
收藏
页码:2294 / 2302
页数:9
相关论文
共 56 条
[51]  
Spencer DM, 2000, CURR OPIN MOL THER, V2, P433
[52]   An inducible caspase 9 safety switch for T-cell therapy [J].
Straathof, KC ;
Pulè, MA ;
Yotnda, P ;
Dotti, G ;
Vanin, EF ;
Brenner, MK ;
Heslop, HE ;
Spencer, DM ;
Rooney, CM .
BLOOD, 2005, 105 (11) :4247-4254
[53]   A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease [J].
Thomis, DC ;
Marktel, S ;
Bonini, C ;
Traversari, C ;
Gilman, M ;
Bordignon, C ;
Clackson, T .
BLOOD, 2001, 97 (05) :1249-1257
[54]   Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft [J].
Tiberghien, P ;
Ferrand, C ;
Lioure, B ;
Milpied, N ;
Angonin, R ;
Deconinck, E ;
Certoux, JM ;
Robinet, E ;
Saas, P ;
Petracca, B ;
Juttner, C ;
Reynolds, CW ;
Longo, DL ;
Herve, P ;
Cahn, JY .
BLOOD, 2001, 97 (01) :63-72
[55]   Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors [J].
Verzeletti, S ;
Bonini, C ;
Marktel, S ;
Nobili, N ;
Ciceri, F ;
Traversari, C ;
Bordignon, C .
HUMAN GENE THERAPY, 1998, 9 (15) :2243-2251
[56]   Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo [J].
Yee, C ;
Thompson, JA ;
Roche, P ;
Byrd, DR ;
Lee, PP ;
Piepkorn, M ;
Kenyon, K ;
Davis, MM ;
Riddell, SR ;
Greenberg, PD .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) :1637-1643